Potential of antibody test using Schistosoma mansoni recombinant serpin and RP26 to detect light-intensity infections in endemic areas

Tanaka, Mio; Kildemoes, Anna Overgaard; Chadeka, Evans Asena; Cheruiyot, Benard Ngetich; Sassa, Miho; Moriyasu, Taeko; Nakamura, Ryô; Kikuchi, Mihoko; Fujii, Yoshito; Dood, Claudia J. de; Corstjens, Paul L. A. M.; Kaneko, Satoshi; Maruyama, Haruhiko; Njenga, Sammy M.; Vrueh, Remco de; Hokke, Cornelis H.; Hamano, Shinjiro

doi:10.1016/j.parint.2021.102346

Cited by 7 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present review S . mansoni RP26 a member of the SAPLIP multi-gene family was reported to have sensitivities ranging from 67.80% [Serum IgG luminex immunoassay] to 100% [Serum IgG Western blot] and specificities ranging from 57.4% [Serum IgG ELISA] to 100% [Serum IgG Western blot] [ 17 , 40 ]. It was furthermore noted that RP26 may be particularly useful in developing tools for monitoring progress of chemotherapy intervention by detecting new infections.…”

Section: Resultsmentioning

confidence: 99%

“…SERPINS are interesting immunodiagnostic targets, due to their presence at the parasite-host interface, where they are crucial for the adaptation and survival of the parasite to the host environment by modulating inflammatory response [ 17 ]. Amongst the studies that have investigated S .…”

Section: Resultsmentioning

confidence: 99%

“…However, the method is expensive and requires skilled personnel which are not readily available in remote rural settings [ 7 , 16 ]. The point-of-care circulating cathodic antigen test is considerably more sensitive than the Kato-Katz technique but shows low sensitivity when compared to ELISA in low infection intensity cases [ 17 , 18 ]. Moreover, it has been noted that the POC-CCA tends to give false negative results for light intensity infections [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic performances of Schistosoma haematobium and Schistosoma mansoni recombinant proteins, peptides and chimeric proteins antibody based tests. Systematic scoping review

Vengesai

Muleya²,

Midzi³

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Traditional diagnostic tests for schistosome infections are suboptimal, particularly when the parasite burden is low. In the present review we sought to identify recombinant proteins, peptides, and chimeric proteins with potential to be used as sensitive and specific diagnostic tools for schistosomiasis. Methods The review was guided by PRISMA-ScR guidelines, Arksey and O’Malley’s framework, and guidelines from the Joanna Briggs Institute. Five databases were searched: Cochrane library, PubMed, EMBASE, PsycInfo and CINAHL, alongside preprints. Identified literature were assessed by two reviewers for inclusion. A narrative summary was used to interpret the tabulated results. Results Diagnostic performances were reported as specificities, sensitivities, and AUC. The AUC for S. haematobium recombinant antigens ranged from 0.65 to 0.98, and 0.69 to 0.96 for urine IgG ELISA. S. mansoni recombinant antigens had sensitivities ranging from 65.3% to 100% and specificities ranging from 57.4% to 100%. Except for 4 peptides which had poor diagnostic performances, most peptides had sensitivities ranging from 67.71% to 96.15% and specificities ranging from 69.23% to 100%. S. mansoni chimeric protein was reported to have a sensitivity of 86.8% and a specificity of 94.2%. Conclusion The tetraspanin CD63 antigen had the best diagnostic performance for S. haematobium. The tetraspanin CD63 antigen Serum IgG POC-ICTs had a sensitivity of 89% and a specificity of 100%. Peptide Smp_150390.1 (216–230) serum based IgG ELISA had the best diagnostic performance for S. mansoni with a sensitivity of 96.15% and a specificity of 100%. Peptides were reported to demonstrate good to excellent diagnostic performances. S. mansoni multi-peptide chimeric protein further improved the diagnostic accuracy of synthetic peptides. Together with the advantages associated with urine sampling technique, we recommend development of multi-peptide chimeric proteins urine based point of care tools.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic performances of Schistosoma haematobium and Schistosoma mansoni recombinant proteins, peptides and chimeric proteins antibody based tests. Systematic scoping review

Vengesai

Muleya²,

Midzi³

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Nickel et al (2015) reported that soluble adult worm antigen (SWAP) prepared from S. mansoni showed 94.5% sensitivity in ELISA for diagnosis of S. mekongi infection in humans [ 50 ]. However, the preparation of crude antigens such as SEA and SWAP is problematic due to observed low yields and poor quality control [ 51 ]. In addition, wide and high cross-reactions against other trematode infections are of concern when they are used in prevalence surveys [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Cloning, Expression and Evaluation of Thioredoxin Peroxidase-1 Antigen for the Serological Diagnosis of Schistosoma mekongi Human Infection

et al. 2022

View full text Add to dashboard Cite

Schistosoma mekongi, a blood fluke that causes Asian zoonotic schistosomiasis, is distributed in communities along the Mekong River in Cambodia and Lao People’s Democratic Republic. Decades of employing numerous control measures including mass drug administration using praziquantel have resulted in a decline in the prevalence of schistosomiasis mekongi. This, however, led to a decrease in sensitivity of Kato–Katz stool microscopy considered as the gold standard in diagnosis. In order to develop a serological assay with high sensitivity and specificity which can replace Kato–Katz, recombinant S. mekongi thioredoxin peroxidase-1 protein (rSmekTPx-1) was expressed and produced. Diagnostic performance of the rSmekTPx-1 antigen through ELISA for detecting human schistosomiasis was compared with that of recombinant protein of S. japonicum TPx-1 (rSjTPx-1) using serum samples collected from endemic foci in Cambodia. The sensitivity and specificity of rSmekTPx-1 in ELISA were 89.3% and 93.3%, respectively, while those of rSjTPx-1 were 71.4% and 66.7%, respectively. In addition, a higher Kappa value of 0.82 calculated between rSmekTPx-1 antigen ELISA and Kato–Katz confirmed better agreement than between rSjTPx-1 antigen ELISA and Kato–Katz (Kappa value 0.38). These results suggest that ELISA with rSmekTPx-1 antigen can be a potential diagnostic method for detecting active human S. mekongi infection.

show abstract

“…Detection of antibodies against these proteins is appealing because some of the proteins, especially from the gut, are products of active worm activity, suggesting that positivity will be evidence of active infections. In addition, these proteins will minimize the challenges of cross reactivity in coinfections and have a higher specificity compared to antibody response to crude antigen (SEA) in low endemic setting ( 198 , 199 ). Two gut saposins, SjSAPLP4 and SjSAPLP5, likely to be prominent in S. japonicum vomitus have been used in ELISA format to detect schistosome infections in laboratory animals and human patients in China ( 200 ) and the Philippines ( 201 ).…”

Section: Diagnosis Of Schistosoma Species Infectionsmentioning

confidence: 99%

The Road to Elimination: Current State of Schistosomiasis Research and Progress Towards the End Game

et al. 2022

View full text Add to dashboard Cite

The new WHO Roadmap for Neglected Tropical Diseases targets the global elimination of schistosomiasis as a public health problem. To date, control strategies have focused on effective diagnostics, mass drug administration, complementary and integrative public health interventions. Non-mammalian intermediate hosts and other vertebrates promote transmission of schistosomiasis and have been utilized as experimental model systems. Experimental animal models that recapitulate schistosomiasis immunology, disease progression, and pathology observed in humans are important in testing and validation of control interventions. We discuss the pivotal value of these models in contributing to elimination of schistosomiasis. Treatment of schistosomiasis relies heavily on mass drug administration of praziquantel whose efficacy is comprised due to re-infections and experimental systems have revealed the inability to kill juvenile schistosomes. In terms of diagnosis, nonhuman primate models have demonstrated the low sensitivity of the gold standard Kato Katz smear technique. Antibody assays are valuable tools for evaluating efficacy of candidate vaccines, and sera from graded infection experiments are useful for evaluating diagnostic sensitivity of different targets. Lastly, the presence of Schistosomes can compromise the efficacy of vaccines to other infectious diseases and its elimination will benefit control programs of the other diseases. As the focus moves towards schistosomiasis elimination, it will be critical to integrate treatment, diagnostics, novel research tools such as sequencing, improved understanding of disease pathogenesis and utilization of experimental models to assist with evaluating performance of new approaches.

show abstract

Potential of antibody test using Schistosoma mansoni recombinant serpin and RP26 to detect light-intensity infections in endemic areas

Cited by 7 publications

References 44 publications

Diagnostic performances of Schistosoma haematobium and Schistosoma mansoni recombinant proteins, peptides and chimeric proteins antibody based tests. Systematic scoping review

Diagnostic performances of Schistosoma haematobium and Schistosoma mansoni recombinant proteins, peptides and chimeric proteins antibody based tests. Systematic scoping review

Cloning, Expression and Evaluation of Thioredoxin Peroxidase-1 Antigen for the Serological Diagnosis of Schistosoma mekongi Human Infection

The Road to Elimination: Current State of Schistosomiasis Research and Progress Towards the End Game

Contact Info

Product

Resources

About